Ahidjo Bintou A, Loe Marcus Wing Choy, Ng Yan Ling, Mok Chee Keng, Chu Justin Jang Hann
NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore.
Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.
ACS Infect Dis. 2020 Jul 10;6(7):1624-1634. doi: 10.1021/acsinfecdis.0c00236. Epub 2020 Jun 16.
COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 and also clinically to treat this disease. This review article discusses the main antiviral strategies currently employed and summarizes reported and efficacies of key antiviral compounds in use.
2020年3月11日，世界卫生组织宣布新型冠状病毒肺炎（COVID-19）为大流行病。这种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的新型冠状病毒疾病在全球范围内造成了严重且前所未有的社会和经济混乱。自2019年12月发现COVID-19以来，人们已经对多种抗病毒药物进行了抗SARS-CoV-2疗效测试，并在临床上用于治疗这种疾病。这篇综述文章讨论了目前采用的主要抗病毒策略，并总结了已报道的主要抗病毒化合物的疗效。
